PPCB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Propanc Biopharma Inc (PPCB) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks clear positive catalysts, has weak financial performance, and no significant trading or sentiment signals to support a buy decision.
The stock's MACD is slightly positive but contracting, RSI is neutral at 39.294, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are at 0.232 and 0.245, while support levels are at 0.188 and 0.175. Overall, the technical indicators suggest a bearish trend.
NULL identified. No recent news, trading trends, or significant signals to indicate a positive outlook.
Weak financial performance with no revenue growth, significant net income loss (-4023640), and a sharp EPS decline (-99.07% YoY). No recent insider, hedge fund, or congress trading activity to suggest confidence in the stock.
In Q2 2026, the company reported no revenue growth (0% YoY), a net income loss of -4023640 (up 835.33% YoY due to prior losses), and a sharp EPS decline to -0.3 (-99.07% YoY). Gross margin remains at 0.
No analyst ratings or price target changes available.
